South AfricaTuberculosis profile
Population  2015 54 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 25 (21–29) 46 (39–53)
Mortality (HIV+TB only) 73 (27–140) 133 (50–256)
Incidence  (includes HIV+TB) 454 (294–649) 834 (539–1 190)
Incidence (HIV+TB only) 258 (165–370) 473 (303–680)
Incidence (MDR/RR-TB)** 20 (13–27) 37 (24–50)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 16 (6.9–25) 175 (91–260) 191 (98–285)
Males 17 (9.8–23) 246 (173–320) 263 (182–343)
Total 33 (21–44) 422 (327–516) 454 (294–649)
TB case notifications, 2015  
Total cases notified 294 603
Total new and relapse 287 224
          - % tested with rapid diagnostics at time of diagnosis 64%
          - % with known HIV status 97%
          - % pulmonary 90%
          - % bacteriologically confirmed among pulmonary 60%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 63% (44–98)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.22 (0.1–0.42)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 157 505 57%
          - on antiretroviral therapy 133 116 85%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  10 000
(8 200–12 000)
Estimated % of TB cases with MDR/RR-TB 3.5% (2.8–4.2) 7.1% (5.3–8.9)  
% notified tested for rifampicin resistance 65% 71% 196 783
MDR/RR-TB cases tested for resistance to second-line drugs   7 402
Laboratory-confirmed cases MDR/RR-TB: 19 613, XDR-TB: 1 024
Patients started on treatment **** MDR/RR-TB: 12 527, XDR-TB: 730
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 78% 319 752
Previously treated cases, excluding relapse, registered in 2014 63% 4 652
HIV-positive TB cases, all types, registered in 2014 76% 183 697
MDR/RR-TB cases started on second-line treatment in 2013 48% 10 614
XDR-TB cases started on second-line treatment in 2013 24% 611
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 38%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 425
Funding source: 87% domestic, 8% international, 5% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-11 Data: www.who.int/tb/data